Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) ended Friday session in green amid volatile trading. The shares closed up +0.03 points or 0.54% at $5.61 with 2.70 million shares getting traded. Post opening the session at $5.56, the shares hit an intraday low of $5.55 and an intraday high of $5.66 and the price vacillated in this range throughout the day. The company has a market cap of $1.01 billion and the numbers of outstanding shares have been calculated to be 179.45 million shares.
Synergy Pharmaceuticals Inc (SGYP) announced that it will present at the OctoberINVESTfest Conference on Wednesday, September 28, 2016 at 11:30 a.m. Eastern Time at the New York Academy of Sciences in New York.
A live webcast of the presentation will be accessible through the Investor Relations section of the company’s website at www.synergypharma.com. A replay of the webcast will be available on Synergy’s website for 60 days following the conference.
Shares of Allergan plc Ordinary Shares (NYSE:AGN) ended Friday session in green amid volatile trading. The shares closed up +0.51 points or 0.21% at $243.94 with 2.69 million shares getting traded. Post opening the session at $242.49, the shares hit an intraday low of $242.49 and an intraday high of $146.50 and the price vacillated in this range throughout the day. The company has a market cap of $96.39 billion and the numbers of outstanding shares have been calculated to be 395.95 million shares.
Allergan plc Ordinary Shares (AGN) on Sept. 23, 2016 announced the company has received approval from the U.S. Food and Drug Administration (FDA) to market NATRELLE INSPIRA® Cohesive breast implants, offering women undergoing reconstruction, augmentation or revision surgery a new breast shaping option that combines a high gel fill ratio and Allergan’s highly cohesive gel for a customized result. The new NATRELLE INSPIRA® Cohesive line of breast implants is the newest entry into the category of breast implants commonly referred to as “gummy” implants, designed for women who are interested in increased breast fullness.
“NATRELLE INSPIRA® Cohesive breast implants are just the latest example of our commitment to innovation in breast aesthetics and plastic surgery, and we are proud that we are able to continue to offer advancements in technology that allow physicians and their patients more options,” said David Nicholson, Chief R&D Officer of Allergan plc. “NATRELLE INSPIRA® Cohesive allows patients to get the same high gel fill ratio and fullness offered by the NATRELLE INSPIRA® line of implants, with our highly cohesive, form-stable gel.”
The FDA approval of NATRELLE INSPIRA® Cohesive breast implants, which are available with both smooth and BIOCELL® textured surfaces, marks the most recent addition to the broad portfolio of currently available NATRELLE® products in the US. The smooth version of the NATRELLE INSPIRA® round gel-filled breast implants with responsive gel was approved by FDA in February 2015, and the textured version of the NATRELLE INSPIRA®round gel-filled breast implants with responsive gel were approved by the FDA in June 2015.